Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GC Pharma Sells N American Plasma Units To Grifols As Pandemic Prolongs

$460m Package Deal

Executive Summary

The South Korean pharma firm, which has been focusing on North America, decides to sell two subsidiaries there as the prolonged coronavirus pandemic further delays commercial manufacturing of plasma products. 

You may also be interested in...



GC Pharma Preps For Life After Sale Of North American Subsidiaries

South Korean firm outlines R&D milestones for this year including progress with a plasma therapy for COVID-19, as well as other challenges and opportunities amid the pandemic.

GC Pharma Hones R&D Focus, Tweaks US Immunoglobulin Strategy

Leading South Korean pharma firm GC Pharma realigns R&D priorities and resources and changes US strategy amid delayed approval of its immunoglobulin product.

Korean Firms Pursue “Select And Focus” Strategy To Accelerate R&D

South Korean pharma and biotech companies are opting to spin off certain businesses and set up new subsidiaries to speed up R&D progress and tap funding opportunities. The move, which has become more visible in the past few years is in line with global biopharma trends, although the reasons may vary.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel